Compare GE Vernova Inc (GEV) vs Heron Therapeutics Inc (HRTX) Price & Performance

GE Vernova (GEV) trades at $1,038, down 2.63% today, with mixed technical signals showing bearish overall momentum but bullish moving averages. The company demonstrates strong profitability with 23.81% net income margin and 83.23% ROE, though valuation metrics appear elevated with P/E of 30.84 and EV/EBITDA of 109.82. Recent earnings showed volatility with Q1 2026 beating expectations by a wide margin, while the company prepares for Q2 2026 results amid significant AI-driven power demand growth.

The outlook remains positive with analyst consensus strongly bullish (21 buy ratings, 0 sell) and $1,260 price target representing 21% upside. Key opportunities include AI data center power demand and $11 billion investment push, while risks include wind segment pressures and elevated valuation multiples that may limit near-term upside potential despite strong fundamentals.

HRTX trades at $0.44, up 2.63% today, with a bullish technical signal but bearish moving averages. The company reported Q1 2026 revenue of $151M with a net loss of $31M, maintaining a negative profit margin of -20.53%. Recent patent litigation developments and mixed earnings performance create uncertainty, though analyst consensus remains overwhelmingly positive with 94.7% buy ratings.

The outlook remains challenging with persistent losses and negative cash flow from operations, though improving net cash flow trends offer some optimism. Key risks include ongoing patent litigation and execution challenges in achieving profitability. The strong analyst support suggests potential upside if the company can deliver on its guidance and improve operational efficiency.